Caution before canonisation: a clinical and implementation science perspective on psychedelics.
- 1Centre for Research in Intellectual and Developmental Disabilities, University of Warwick, Coventry, United Kingdom.
- 2Specialized Psychodiagnostic and Evidence-Based Consultation Services, Code Behaviour/Modus Mores, Nicosia, Cyprus.
Abstract
Recent advances in psychedelic research have renewed interest in the potential therapeutic role of psychedelic-assisted interventions in psychiatry. Early clinical trials suggest that compounds such as psilocybin and MDMA, administered within structured therapeutic frameworks, may produce rapid symptom improvements for conditions including depression, post-traumatic stress disorder, and substance use disorders. While these findings are scientifically promising, the current evidence base remains characterized by methodological and translational limitations. Many studies involve small samples, short follow-up periods, functional unblinding, and heterogeneous safety reporting, which complicate causal interpretation and generalizability. In the present paper, we examine psychedelic therapies through clinical, methodological, ethical, and implementation science lenses. We argue that current trials primarily demonstrate proof-of-concept efficacy under controlled conditions rather than readiness for large-scale clinical adoption. Responsible translation therefore requires stronger evidence regarding durability, safety monitoring, comparative effectiveness, and real-world implementation. Psychedelic therapies represent an important emerging research direction, but continued rigorous evaluation and improved implementation of established evidence-based interventions remain central to addressing mental disorders.
Related
- AI literacy as a core competency for health professionals: A consolidated framework for implementation research (CFIR)-Informed perspective
- Advancing Social Connection Through Social Prescribing: A Translational and Implementation Science Perspective
- Acute deoxygenation during M-TEER: a note of caution
- Facilitators and barriers influencing the implementation of type 2 diabetes remission programmes: a qualitative meta-synthesis from a multi-stakeholder perspective
- Sarcopenia and Muscle Dysfunction in Older Adults with Burn Injuries: An Integrated Clinical Perspective
BibTeX
@article{paris2026caution,
title = {{Caution before canonisation: a clinical and implementation science perspective on psychedelics.}},
author = {Andreas Paris and Foteini Thoma and Aikaterini Velentza and Panagiota Pavlopoulou and Giorgos Metaxas},
journal = {Frontiers in psychiatry},
year = {2026},
month = oct,
doi = {10.3389/fpsyt.2026.1922928},
url = {https://europepmc.org/article/MED/42898320},
note = {CC BY},
}
RIS
TY - JOUR
TI - Caution before canonisation: a clinical and implementation science perspective on psychedelics.
AU - Andreas Paris
AU - Foteini Thoma
AU - Aikaterini Velentza
AU - Panagiota Pavlopoulou
AU - Giorgos Metaxas
PY - 2026
DA - 2026/10/05
JO - Frontiers in psychiatry
DO - 10.3389/fpsyt.2026.1922928
UR - https://europepmc.org/article/MED/42898320
AB - Recent advances in psychedelic research have renewed interest in the potential therapeutic role of psychedelic-assisted interventions in psychiatry. Early clinical trials suggest that compounds such as psilocybin and MDMA, administered within structured therapeutic frameworks, may produce rapid symptom improvements for conditions including depression, post-traumatic stress disorder, and substance use disorders. While these findings are scientifically promising, the current evidence base remains characterized by methodological and translational limitations. Many studies involve small samples, short follow-up periods, functional unblinding, and heterogeneous safety reporting, which complicate causal interpretation and generalizability. In the present paper, we examine psychedelic therapies through clinical, methodological, ethical, and implementation science lenses. We argue that current trials primarily demonstrate proof-of-concept efficacy under controlled conditions rather than readiness for large-scale clinical adoption. Responsible translation therefore requires stronger evidence regarding durability, safety monitoring, comparative effectiveness, and real-world implementation. Psychedelic therapies represent an important emerging research direction, but continued rigorous evaluation and improved implementation of established evidence-based interventions remain central to addressing mental disorders.
SN - 1664-0640
ER -